- Investor's Business Daily•12 hours ago
Gilead will likely guide to declining 2017 sales, hamstrung on limited Hep C visibility, RBC said Wednesday.
- Zacks•16 hours ago
Concert Pharmaceuticals, Inc. (CNCE) provided update on the development plan of its next generation CFTR potentiator, CTP-656, for the treatment of cystic fibrosis in the U.S. and Europe.
- Zacks•20 hours ago
Vertex Pharmaceuticals (VRTX) has seen positive earnings estimate revisions for the current quarter and year, in addition to decent short-term price momentum.
VRTX : Summary for Vertex Pharmaceuticals Incorpor - Yahoo Finance
Vertex Pharmaceuticals Incorporated (VRTX)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||75.00 x 100|
|Ask||87.64 x 100|
|Day's Range||81.58 - 82.87|
|52 Week Range||71.46 - 103.73|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-72.77|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|